Product Launch Tracker: eHCPs celebrated the first approved treatment for patients with NASH

02.04.2024 | Tracker

Product Launch Tracker: eHCPs celebrated the first approved treatment for patients with NASH

Every month,’s tracking updates bring you the latest insights from the online conversation of healthcare professionals (eHCPs) across the globe discussing product launches. Discover which new drug approvals eHCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in’s latest tracking update.


Throughout March 2024 tracked the global conversations of 1688 HCPs who posted 2577 tweets about the launches and approvals of new products.

In March, 277 more eHCPs discussed treatment approvals than in February, publishing  23% more posts during that time.

On 14 March, the FDA approved Madrigal Pharmacautical’s Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring.  Online HCPs were thrilled about the approval as it is the first treatment approved for NASH. It represents a breakthrough for patients and offers them hope, said Dr Jan Kral, a gastroenterologist. Hepatologist Dr Naim Alkhouri characterised the day of the approval as a ‘historic day for the NASH space’. Many eHCPs celebrated the news calling it a ‘hurrah moment’ for patients and bringing the promise of much progress to come

On 8 March, the FDA approved a new indication for Novo Nordisk’s Wegovy (semaglutide) injection to reduce the risk of heart attack and stroke in adults with cardiovascular disease and obesity or overweight. Most eHCPs were pleased with the new indication approval, calling it “a big win”. Other eHCPs such as Dr Matthew Bowdish posted about the positive outcomes of the SELECT trial. A few eHCPs also commented the new indication will improve and expand insurance coverage for weight loss treatments.

On 1 March, the FDA approved Boston Scientific’s Agent paclitaxel-coated balloon, the first such balloon to be approved for the treatment of coronary in-stent restenosis. A few eHCPs who shared the news expressed their enthusiasm for the new treatment. They also highlighted the benefits of the new treatment compared to conventional angioplasty and discussed the positive outcomes of the trial with their peers.

The three most shared stories from eHCPs discussing product launches in March were:

Each month, tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area-specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to’s monthly eJournal.


  • CREATION Pinpoint® listened to the discussions amongst online HCPs of pharmaceutical product launches and drug approvals between 1 March and 31 March 2024.  
  • The data included mentions of drug approvals by the FDA, EMA, NICE, and CHMP, as well as HCPs’ use of the phrase ‘drug approval’ in their tweets.
  • Between 1 and 31 March 2024, 2517 online HCPs worldwide made 1688 references to new pharmaceutical product launches and drug approvals. 


Share this article

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next

SGLT2 inhibitors: an emerging option for cardiologists?

05.09.2018 | Article

SGLT2 inhibitors: an emerging option for cardiologists?

SGLT2 inhibitors: an emerging option for cardiologists?

By Daniel Ghinn

12.06.2023 | Article

Top 50 Pharma tracker review: The importance of knowing what HCPs think.

Looking at the corporate reputation of the Top 50 pharma companies over the past year

By Francesca Gan

View all articles >